Compounds > sb 203580
Page last updated: 2024-09-05

sb 203580 and rwj 67657

sb 203580 has been researched along with rwj 67657 in 5 studies

Compound Research Comparison

Studies
(sb 203580)		Trials
(sb 203580)		Recent Studies (post-2010)
(sb 203580)		Studies
(rwj 67657)		Trials
(rwj 67657)		Recent Studies (post-2010) (rwj 67657)
3,48941,13734413

Protein Interaction Comparison

ProteinTaxonomysb 203580 (IC50)rwj 67657 (IC50)
Mitogen-activated protein kinase 14Homo sapiens (human)1

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brumlik, MJ; Burow, ME; Curiel, TJ; Daniel, BJ; Khan, IA; Siekierka, J; Wadsworth, S; Wei, S; Zou, W1
Henne, WA; Kularatne, SA; Low, PS; Santhapuram, HK; Vaitilingam, B; Venkatesh, C; Wang, K1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Bhat, R; Canan, S; Chojnowski, A; Goldberg, R; Hawryluk, N; Khetani, V; Kreiss, T; Mortensen, D; Prorok, M; Rotella, DP; Siekierka, JJ; Tummalapalli, SR; Zeldis, J1
Beers, SA; Cavender, DE; Davis, JE; Fahmy, B; Lalan, P; Malloy, EA; Olini, GC; Pellegrino-Gensey, JL; Schafer, PH; Siekierka, JJ; Wachter, MP; Wadsworth, SA; Wu, W1

Other Studies

5 other study(ies) available for sb 203580 and rwj 67657

ArticleYear
Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:12

    Topics: Animals; Antiprotozoal Agents; CD8 Antigens; Dose-Response Relationship, Drug; Drug Design; Drug Synergism; Drug Therapy, Combination; Encephalitozoon cuniculi; Encephalitozoonosis; Enzyme Inhibitors; Female; Humans; Imidazoles; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; p38 Mitogen-Activated Protein Kinases; Pyridines; Time Factors; Toxoplasma; Toxoplasmosis, Animal

2007
Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs.
    Journal of medicinal chemistry, 2010, Nov-11, Volume: 53, Issue:21

    Topics: Antigens, Surface; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Glutamate Carboxypeptidase II; Glutarates; Humans; Ligands; Male; Molecular Targeted Therapy; Prodrugs; Prostatic Neoplasms; Structure-Activity Relationship; Urea

2010
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Discovery of a Stress-Activated Protein Kinase Inhibitor for Lymphatic Filariasis.
    ACS medicinal chemistry letters, 2018, Mar-08, Volume: 9, Issue:3

    Topics:

2018
RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.
    The Journal of pharmacology and experimental therapeutics, 1999, Volume: 291, Issue:2

    Topics: Animals; Antigens; Cell Division; Dogs; Dose-Response Relationship, Drug; Enterotoxins; Enzyme Inhibitors; Humans; Imidazoles; In Vitro Techniques; Interferon-gamma; Interleukin-2; Lipopolysaccharides; Macrophages; Male; Mice; Mitogen-Activated Protein Kinases; Monocytes; Protein Kinases; Pyridines; Rats; Rats, Inbred Lew; Staphylococcus; T-Lymphocytes; Tumor Necrosis Factor-alpha

1999